BPM Secures Regulatory Approval in Brazil, Tapping into a $10+ Billion Healthcare Market

Following the market authorization obtained in Guatemala last week, Bio Preventive Medicine Corp. ("BPM", Stock Code: 6810) announced today (27th) that its proprietary innovative diagnostic test, DNlite-IVD103, has been granted market authorization by the Brazilian Health Regulatory Agency (ANVISA). The approved indication is for the risk assessment and prediction of Diabetic Kidney Disease (DKD) in patients with Type 2 diabetes.

A Strategic Foothold in the LATAM Market

BPM stated that Brazil is not only the largest economy in Latin America but also the largest medical device market in South America. The market opportunities in Brazil have always been a highly coveted strategic prize for global enterprises, making this successful approval exceptionally significant. Furthermore, backed by patent protection in Brazil, DNlite-IVD103 is well-positioned to secure its technological leadership and accelerate market penetration. The company currently plans to expand into the broader LATAM market through a co-distribution model and is already in active discussions with potential partners.

Addressing a Colossal Unmet Need

According to data from the International Diabetes Federation (IDF), there are approximately 15.73 million adult diabetic patients in Brazil, ranking the country sixth globally and first in Latin America for diabetes prevalence. In 2021, diabetes-related healthcare expenditures in Brazil reached a staggering $42.9 billion USD, underscoring a massive underlying market for precision medical care and management.       

Accelerating Global Regulatory and Commercial Momentum

DNlite-IVD103 is the world's first ELISA-based diagnostic test designed to prevent the rapid progression of Diabetic Kidney Disease. Prior to Brazil, the test had already secured market authorizations in the EU, Taiwan, Malaysia, Thailand, Saudi Arabia, the United Arab Emirates, Vietnam, Indonesia, and Guatemala.

With this latest approval in South America's largest nation, BPM's global regulatory clearances are rapidly accelerating. The company is actively advancing commercial collaborations and establishing distribution channels across these regions. As the strategic benefits of this multifaceted global footprint begin to materialize, BPM anticipates robust revenue growth and maintains a highly optimistic outlook for its operations in the coming year.

Related Links:

新穎生醫檢測試劑DNlite-DKD uPTM-FetA ELISA Kit獲巴西ANVISA核發上巿許可 MoneyDJ

新穎創新檢測試劑獲巴西上市許可 攻逾百億美元照護商機 工商時報

新穎生醫DNlite-IVD103再取巴西上市許可攻拉丁美洲糖尿病市場  環球生技